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Introduction: The Japanese Respiratory Society Guidelines for the Management of Commu-
nity-Acquired Pneumonia (CAP) in Adults (JRS 2005) was published as a revision of the Basic
Concept for the Management of CAP in Adults (JRS 2000). To evaluate the JRS 2005 criteria
for differentiating between disease types and assessing the status of antimicrobial agent
use in initial treatment, we conducted a prospective survey.
Subjects and methods: The survey was conducted from July 2006 to March 2007 as a
nationwide joint study by 200 institutions. The study subjects included patients aged Z16
years of age who had CAP, and patients who met the inclusion criteria were consecutively
enrolled. Disease type differentiation based on JRS 2005 and JRS 2000 was conducted.
Disease type diagnosis was also performed based on test results. The sensitivity and
specificity of disease type differentiation were calculated. The antimicrobial agents used in
the initial treatment were classified as recommended or non-recommended based on JRS
2005. The validity of non-recommended antimicrobial agent use was investigated.
Results: A total of 1875 patients were analyzed. Differentiation of atypical pneumonia using
the JRS 2005 criteria had higher sensitivity and lower specificity than differentiation using
the JRS 2000 criteria. The antimicrobial agents recommended by JRS 2005 were used as
initial treatment in a low number of cases. The efficacy of the recommended antimicrobial
agents was similar to that of the non-recommended agents.anese Respiratory Society. Published by Elsevier B.V. All rights reserved.
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R E S P I R ATO RY I N V E S T I G AT I O N 50 ( 2012 ) 23 –3224Conclusions: JRS 2005 is advantageous in terms of reducing the number of items used in
disease type differentiation. The recommended antimicrobial agents used for the initial
treatment are believed to be appropriate.
& 2012 The Japanese Respiratory Society. Published by Elsevier B.V. All rights reserved.1. Introduction
In 2000, the Japanese Respiratory Society (JRS) published
‘‘Basic Concepts in the Medical Care of Community-
Acquired Pneumonia (CAP) in Adults’’ (JRS 2000) [1], which
proposed standardized practices for the treatment of
pneumonia in Japan. In 2005, the ‘‘Guidelines for the
Management of CAP in Adults’’ (JRS 2005) [2] were issued.
JRS 2005 is a revision of JRS 2000 mainly in terms of the
criteria for judging severity and differentiating between
bacterial and atypical pneumonia. We conducted a nation-
wide, multicenter joint study to investigate the validity of
the criteria for judging severity and differentiating disease
types, and to clarify the status of antimicrobial agent use in
initial treatment. We report here the validity of the criteria
for differentiating disease types and the status of anti-
microbial agent use in initial treatment.2. Subjects and methods
2.1. Participating institutions and survey period
The survey was conducted between July 2006 and March
2007 nationwide at 200 institutions with respiratory spe-
cialists (Table 1). Patients who met the enrollment criteria
were consecutively enrolled in the order which medication
was started until the predetermined number of cases was
reached.2.2. Subjects
The study subjects included patients aged Z16 years of age
who had CAP and presented with clinical symptoms, such as
cough, sputum, and fever, and had infiltrative shadows that
appeared suddenly on chest X-ray, chest computed tomogra-
phy, or other imaging modalities. Patients who developed
pneumonia Z48 h after entering the hospital (hospital-
acquired pneumonia) or improved after pretreatment with
antimicrobial agents were excluded.2.3. Observation and test items
Patient background and clinical symptoms, including body
temperature and sputum, were confirmed at initial con-
sultation. Chest X-rays and clinical tests were performed
before and after administering medication. A rapid diag-
nosis was made as soon as possible, and antibody levels
and bacteriological test (culture) results were also con-
firmed.2.4. Diagnosis based on the results of disease type
differentiation and tests conducted at initial examination
2.4.1. Disease type differentiation at initial consultation
The criteria for differentiating disease type in JRS 2005 include
6 clinical features: (1) age o60 years; (2) no or minor
underlying disease; (3) the presence of stubborn cough; (4)
poor chest auscultation findings; (5) no sputum or no
etiological agent identified in the rapid diagnosis; and (6) a
peripheral white blood cell counto10,000 cells/mL. Using all 6
items (6-item assessment) or 5 items of 6 items, excluding
item 6 (5-item assessment), ‘‘suspected atypical pneumonia’’
is differentiated if Z4 of the 6 items or Z3 of the 5 items are
positive, and ‘‘suspected bacterial pneumonia’’ is differen-
tiated if r3 of the 6 items or r2 of the 5 items are positive.
Three additional clinical features are: (7) a cluster of
pneumonia among family members or close associates; (8)
the presence of relative bradycardia; and (9) ground glass
opacity or skip lesion on chest X-ray. IfZ5 of these 9 items are
positive, the disease type is considered ‘‘suspected atypical
pneumonia,’’ and if r4 are positive, it is considered ‘‘sus-
pected bacterial pneumonia.’’ Disease type differentiation
based on JRS 2000 was also conducted (9-item assessment).
Cases in which Legionella pneumophila was confirmed by a
rapid diagnosis were handled separately as L. pneumophila
pneumonia.2.4.2. Diagnosis of disease type based on test results
Disease type diagnosis was performed based on the results of
atypical pneumonia test, bacterial culture, and other tests,
and cases were classified as atypical pneumonia (negative
bacteriological culture and positive atypical pneumonia test),
bacterial pneumonia, pneumococcal pneumonia (positive
bacteriological culture, and negative or missing atypical
pneumonia test), L. pneumophila pneumonia (L. pneumophila-
positive by bacteriological culture or rapid diagnosis, regard-
less of the results of any other tests), unknown causative
organism (bacteriological culture or atypical pneumonia test
was missing), and not tested (bacteriological culture and
atypical pneumonia test were missing).
From the disease type diagnosis based on 6- or 9-item
assessment of disease type differentiation conducted at
initial consultation as well as the test results, sensitivity
(the percentage of cases differentiated as suspected atypical
pneumonia among the cases diagnosed as atypical pneumo-
nia) and specificity (the percentage of cases not differen-
tiated as suspected atypical pneumonia among cases not
diagnosed as atypical pneumonia) were calculated. Diagnosis
of atypical pneumonia was performed according to the
criteria for the testing methods used in the investigators’
daily practice.
Table 1 – Institutions participating in this study (1/2).
NTT East Corporation Sapporo Hospital Mitsui Memorial Hospital Kitasato University School of Medicine
Sapporo Hospital of Hokkaido Railway
Company
Toranomon Hospital Sakuramichi Clinic
Sapporo Social Insurance General Hospital Tokyo Kouseinenkin Hospital Tokai University Oiso Hospital
Chitose City Hospital Kanto Central Hospital of the Mutual
Aid Association of Public School
Teachers
Maebashi Red Cross Hospital
Obihiro Kosei General Hospital Toho University Ohashi Medical Center Fujioka General Hospital
Social Welfare Corporation Hokkaido
Social Work Association OBIHIRO Hospital
Kugayama Hospital Tomioka General Hospital
Hokkaido Chuo Rosai Hospital Tokyo Kyosai Hospital Gunma University Graduate School of Medicine
National Hospital Organization Asahikawa
Medical Center
National Hospital Organization Tokyo
Medical Center
Tone Chuo Hospital
National Hospital Organization Hakodate
National Hospital
Tokyo Rosai Hospital Keiaido Hospital
Hakodate Municipal Hospital Kyorin University School of Medicine National Hospital Organization Ibarakihigashi
National Hospital
Hirosaki Chuo Hospital Machida Municipal Hospital National Hospital Organization Mito Medical Center
Akita City Hospital Showa General Hospital Kofu City Hospital
Yamamoto Kumiai Hospital Municipal Akiru Medical Center Ashikaga Red Cross Hospital
Morioka Red Cross Hospital Kawaguchi Municipal Medical Center Utsunomiya Social Insurance Hospital
Tohoku University Graduate School of
Medicine
Saitama Red Cross Hospital Saiseikai Utsunomiya Hospital
Tohoku Kosei Nenkin Hospital Soka Municipal Hospital Iida Municipal Hospital
Sendai Open Hospital Sendai City Medical
Center
Dokkyo Medical University Koshigaya
Hospital
INA Central Hospital
Japanese Red Cross Sendai Hospital Hanyu General Hospital Matsumoto Kyoritsu Hospital
South Miyagi Medical Center Fukaya Red Cross Hospital Nagano Red Cross Hospital
Tohoku Rosai Hospital Saitama Medical University Hospital Nagano Municipal Hospital
Katta General Hospital Nippon Medical School INBA-HITEC
Medical Center
Shinrakuen Hospital
Yonezawa City Hospital Saisei Hospital Sado General Hospital
Sanyudo Hospital Sannoh Hospital Medical Center Niigata Rinko Hospital
Jusendo General Hospital Juntendo University Urayasu Hospital Tachikawa General Hospital
Kashima Hospital Tokyo Dental College Ichikawa General
Hospital
Nagaoka Chuo General Hospital
Kureha General Hospital Showa University Fujigaoka Hospital Niigata Prefectural Muikamachi Hospital
Higashijyujyo Hospital Showa University Yokohama Northern
Hospital
Niigata Rousai Hospital
Juntendo University Nerima Hospital Seirei Yokohama General Hospital Niigataken Saiseikai Sanjo Hospital
Koto Hospital Yokohama Sakae Kyosai Hospital Niigata Prefectural Kamo Hospital
The Fraternity Memorial Hospital Yokohama City University Medical
Center
Nagaoka Red Cross Hospital
Kyoundo Hospital Sasaki Research
Institute
Kawasaki General Hospital Nagoya University Graduate School of Medicine
Juntendo University Japan Labour Health and Welfare
Organization Kanto Rosai Hospital
Nagoya East Municipal Medical Center
Eiju General Hospital Fujisawa City Hospital National Hospital Organization Nagoya Medical
Center
Tosei General Hospital Osaka Koseinenkin Hospital Tottori Seikyo Hospital
Anjo Kosei Hospital Osaka Kaisei Hospital San-in Rosai Hospital
Toyota Kosei Hospital Aichi Prefectural
Welfare Federation of Agricultural
Cooperatives
Aizenbashi Hospital Kagawa Rosai Hospital
Aichi Prefectural Koseiren Showa Hospital Higashiosaka City General Hospital Takamatsu Red Cross Hospital
Japanese Red Cross Nagoya Daiichi
Hospital
Kinki University Faculty of Medicine Tokushima Prefectural Central Hospital
Daiyukai General Hospital PL General Hospital Tokushima Municipal Hospital
Nagoya Ekisaikai Hospital Kishiwada City Hospital Ehime Prefectural Central Hospital
Mie Prefectural General Medical Center Seichokai Fuchu Hospital Ehime University Graduate School of Medicine
KOMONO Hospital Tenri Hospital Matsuyama Shimin Hospital
Mie University Graduate School of
Medicine
Nara Prefectural Nara Hospital Chikamori Hospital
National Hospital Organization, Mie Chuo
Medical Center
Nara Prefectural Gojo Hospital National Hospital Organization Kochi National
Hospital
Hashima City Hospital Yoshino Municipal Hospital Harasanshin Hospital
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Table 1 – (continued)
Gifu Prefectural General Medical Center Nara Medical University Munakata Suikokai General Hospital
Nishimino Welfare Hospital Naga Municipal Hospital Japan Seamen’s Relief Association Moji Hospital
Ogaki Municipal Hospital National Hospital Organization
Minami Wakayama Medical Center
Independent Administrative Agency Japan Labour
Health and Welfare Organization, Kyushu Rosai
Hospital
Yaizu City Hospital Graduate School of Medicine, Kyoto
University
Yame General Hospital
Numazu City Hospital Kyoto First Red Cross Hospital National Hospital Organization Ureshino Medical
Center
Iwata City Hospital Shiga University of Medical Science Sasebo City General Hospital
Kanazawa Red Cross Hospital Shiga Medical Center for Adults Hokusho Central Hospital
Ishikawa-ken Saiseikai Kanazawa Hospital Otsu Red Cross Hospital Nagasaki Rosai Hospital
Kanazawa University Hospital Kobe City Medical Center West
Hospital
Nagasaki Medical Center of Neurology
Kanazawa Social Insurance Hospital Kinki Central Hospital of Mutual Aid
Association of Public School Teachers
Isahaya Health Insurance General Hospital
Kanazawa Medical University Hospital National Hospital Organization Kobe
Medical Center
Omura Municipal Hospital
Ishikawa Prefectural Central Hospital Hyogo Prefectural Kakogawa Medical
Center
Nagasaki University Hospital
Kaga City Hospital National Hospital Organization Himeji
Medical Center
Oita Prefecture Saiseikai Hita Hospital Social Welfare
Organization, Saiseikai Imperial Gift Foundation Inc.
Komatsu Municipal Hospital Hiroshima Prefectural Hospital Oita University Hospital
National Hospital Organization Isikawa
Hospital
Hiroshima Red Cross Hospital and
Atomic Bomb Survirvors Hospital
Oita Prefectural Hospital
Fukui Red Cross Hospital JA Fuchu General Hospital Medical Corporation KEIAI-KAI Oita Nakamura
Hospital
University of Fukui Hospital Kawasaki Medical School Kawasaki
Hospital
Oita Kouseiren Tsurumi Hospital
Fukui Social Insurance Hospital Kurashiki Daiichi Hospital Faculty of Medical and Pharmaceutical Sciences
Kumamoto University
Fukuiken Saiseikai Hospital Kaneda Hospital Japan Labour Health and Welfare Organization
Kumamoto Rosai Hospital
Shinseikai Toyama Hospital Kurashiki Central Hospital University of Miyazaki Hospital
Osaka Red Cross Hospital Simonoseki City Hospital Kagoshima Seikyo Hospital
Nakahama Clinic Tottori Prefectural Central Hospital
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The antimicrobial agent that was initially administered to
treat pneumonia at the study institutions was defined as the
initial treatment. This initial treatment was selected based on
the JRS 2005 ‘‘Key flowchart for initial treatment of CAP in
adults.’’ Efforts were made to administer the antimicrobial
agents for short periods in compliance with the guidelines,
andwith approved dosing. No special restrictions were placed
on combination drugs or therapies.
The antimicrobial agents used were classified as recom-
mended or non-recommended based on the JRS 2005 ‘‘Empiric
treatment for CAP in adults’’ and ‘‘Selection of antimicrobials
when the causative organism has been identified.’’ In other
words, when used for the treatment of suspected bacterial
pneumonia in outpatients without underlying disease or risk
factors, penicillin/b-lactamase inhibitor compounds were
classified as recommended antimicrobial agents, while oral
respiratory quinolones were classified as non-recommended
antimicrobial agents.
In addition, non-recommended antimicrobial agents were
further classified as excessive dosage (combined use of agents
other than the recommended antimicrobial agents, or the use
of agents recommended for more severe cases), inadequatedosage (the use of doses lower than recommended, or the use
of agents recommended for milder cases), inappropriate
agents (the use of agents for which the mechanism of action
cannot be expected to be effective), or unknown (unknown
agents), and the validity of use was investigated.
The clinical effect of the antimicrobial agent used for the
initial treatment at administration, which was either completed
or discontinued, was evaluated with reference to the ‘‘Clinical
evaluation methods for new antimicrobial agents to treat
respiratory infections [3].’’ The agent was considered effective
when Z3 of the following 4 clinical features were satisfied: (1)
defervescence (r37 1C); (2) improvement (normalization) of
peripheral white blood cell count; (3) improvement of C-reactive
protein level (decrease in maximum value to r30%); and (4)
clear improvement of shadows on chest X-ray.2.6. Standardization of judgments
Attempts were made to standardize cases by holding clinical
conferences to discuss whether to adopt problem cases,
how to handle data in cases of deviation from the protocol,
and how to handle causative organisms. For causative
organisms, the appropriateness of a sample and its potential
Table 2 – Number of patients by causative organism assessed by rapid diagnosis or serum antibody.
Tests No. of patients (%) Test results (n)
No. of patients for analysis 1875
Positive Negative Not evaluable
Total Yes 1519 (81.0)
Mycoplasma pneumoniae Yes 1015 (54.1) 214 773 28
Antibody levels 730 (38.9) 157 545 28
CF 342 (18.2) 61 266 15
Single 275 (14.7) 41 219 15
Pair 68 (3.6) 20 48 0
PA 427 (22.8) 100 308 19
Single 311 (16.6) 59 234 18
Pair 117 (6.2) 41 75 1
ImmunoCard 311 (16.6) 66 244 1
Other 22 (1.2) 7 14 1
Chlamydia (Chlamydophila) sp. Yes 527 (28.1) 105 386 36
Antibody levels 515 (27.5) 100 379 36
Single 409 (21.8) 85 289 35
Pair 108 (5.8) 15 92 1
Other 19 (1.0) 7 10 2
Streptococcus pnueumoniae Yes 1121 (59.8) 221 897 3
Urinary antigen 1116 (59.5) 221 892 3
Other 8 (0.4) 3 5 0
Legionella pneumophila Yes 747 (39.8) 10 737 0
Urinary antigen 744 (39.7) 10 734 0
Antibody levels 15 (0.8) 2 13 0
Single 10 (0.5) 2 8 0
Pair 5 (0.3) 0 5 0
Other 1 (0.1) 0 1 0
Other causative organisms Yes 411 (21.9) 12 99 1
Sputum smear 343 (18.3) 6 37 1
Other 109 (5.8) 12 97 0
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were created.
2.7. Statistical analysis
The w2 test and Fisher’s exact test were used for comparisons.3. Results
3.1. Patient background
A total of 1941 patients were enrolled, and 1923 responses
were obtained. In tests for rapid diagnosis, antibody levels,
and other factors, tests for Mycoplasma pneumoniae and
Streptococcus pneumoniae were conducted in at least half of
the cases. ImmunoCards was used in 16.6% of Mycoplasma
tests (Table 2).
3.2. Causative organisms
Identification results for causative organisms by bacteriologi-
cal testing are shown in Fig. 1. The number of cases in which
the causative organism was detected was totaled. In bacterial
pneumonia, the most commonly detected bacterium wasS. pneumoniae, followed by Haemophilus influenzae. Patients
with positive Mycoplasma tests and Chlamydia (Chlamydophila)
tests accounted for 11.4% and 5.6% of atypical pneumonias,
respectively.3.3. Diagnosis based on the results of disease type
differentiation and tests conducted at initial examination
3.3.1. Disease type differentiation at initial consultation
The results of disease type differentiation are shown in Fig. 2.
In a comparison of the 6- and 5-item assessments, the
number of cases judged as suspected atypical pneumonia was
small. Ten patients had L. pneumophila pneumonia.3.3.2. Diagnosis of disease type based on test results
The results of disease type diagnosis based on test results are
shown in Fig. 3. Cases confirmed as bacterial pneumonia as well
as those determined not to be L. pneumophila pneumonia or
atypical pneumonia were classified as bacterial pneumonia.
Cases confirmed as atypical pneumonia and those suspected of
atypical pneumonia were classified as atypical pneumonia.
Mixed infections were seen in 45 bacterial pneumonia and
atypical pneumonia cases.
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Differentiation of atypical pneumonia with the 6-item assess-
ment in JRS 2005 had 71.0% sensitivity and 74.4% specificity
(Table 3); however, the sensitivity and specificity for differentiat-
ing Chlamydia (Chlamydophila) pneumoniae pneumonia were low
compared with those for differentiating M. pneumoniae pneu-
monia. Differentiation with the 9-item assessment of JRS 2000
had high sensitivity, but low specificity.3.4. Initial treatment with antimicrobial agents
The use and efficacy rates of recommended antimicrobial
agents in the 1785 cases in which differentiation of disease
type was done at initial consultation are shown in Table 4.
Recommended antimicrobial agents were used in 35.9% of
cases, including 40.6% of suspected atypical pneumonia cases
and 33.8% of suspected bacterial pneumonia cases. The number
of cases of suspected bacterial pneumonia was particularly low.
The efficacy of recommended antimicrobial agents was
similar to that of non-recommended antimicrobial agents.
Although no significant difference was seen between inpa-
tients and outpatients, for outpatients, the efficacy of
recommended antimicrobial agents was higher than that of
non-recommended antimicrobial agents. For inpatients, the
efficacy of recommended antimicrobial agents was lower
than that of non-recommended antimicrobial agents.
A breakdown of non-recommended antimicrobial agents
shows that excessive dosage was most common, followed by
inadequate dosage and inappropriate agent. Although Z90%
of outpatients had excessive dosage, the efficacy of non-
recommended antimicrobial agents was lower than that of
recommended antimicrobial agents in outpatients. TheM
p
-po
No testing/no causative
organism 54.0%
S. pneumoni
17.2%
*The causative bacterium was counted in one patient 
causative bacteria more than once.
Fig. 1 – Causative organisms deteefficacy of inappropriate agents was also significantly lower
than that of recommended antimicrobial agents (Po0.05). In
cases of excessive dosage, inadequate dosage, and inap-
propriate agent use in inpatients, the efficacy did not differ,
and no significant difference was seen even when compared
to the efficacy of recommended antimicrobial agents
(Table 5).4. Discussion
Immediately after JRS 2000 was issued, a survey was under-
taken, and the results obtained from that survey showed the
need for further measures related to severity, differentiation
between atypical and bacterial pneumonia, severity of under-
lying disease and complications, and adjuvant treatment
other than antimicrobial agent treatment [4].
Although disease type differentiation in JRS 2005 showed
higher sensitivity than in JRS 2000, the specificity was lower
and no great improvements were seen. In addition, in cases
of suspected atypical pneumonia, the sensitivity and speci-
ficity for C. pneumoniae pneumonia were lower than for M.
pneumoniae pneumonia. This is thought to reflect the fact
that current tests for C. pneumoniae pneumonia are not
highly accurate.
In recent years, M. pneumoniae pneumonia has reportedly
become more serious, and differentiating M. pneumoniae
pneumonia from other types of pneumonia is thought to be
an important first step in treatment. Until the accuracy of
tests for C. pneumoniae pneumonia is improved, this method
of differentiation will remain meaningful. At the time JRS
2005 was developed, rapid diagnosis of L. pneumophila
pneumonia and pneumococcal pneumonia had not becomeM. catarrhalis 1.8%
P. aeruginosa 1.3%
Legionella pneumophila
-positive 0.5%
Klebsiella sp. 1.3%
Other 0.6%
Chlamydia (Chlamydophila) sp. -positive 5.6%
ycoplasma
neumoniae
sitive 11.4%
H. influenzae 5.5%
Streptococcus sp. 0.7%
S. aureus 1.2%
ae
who had detected 2 or more
cted by bacteriological testing.
n = 75
n = 10
n = 0
n = 10
n = 153
51 = n978 = n
Suspected bacterial pneumonia
1213 = n265 = n
n = 300 Outpatients n = 205
n = 262 Inpatients n = 1008
Peripheral leukocyte count not tested 
Inpatients
n = 365
n = 393
Outpatients
Outpatients
Inpatients
L. pneumophila pneumonia
Suspected atypical pneumonia
Suspected bacterial pneumoniaSuspected atypical pneumonia
1032 = n857 = n
6 criteria differentiation
Inpatients
Outpatients
Outpatients
Inpatients
Causative organism unknown* n = 1865**
n = 540
5 criteria differentiation
Moderate
n = 808*
Inpatients
n = 680
Outpatients
n = 127
Mild
n = 857
Outpatients
n = 412
Inpatients
n = 445
Outpatients
Inpatients
n = 46
Severe
n = 164
Outpatients
n = 1
Inpatients
n = 163
Very severe
n = 46
Outpatients
n = 0
Inpatients
n = 1334
Ineligible for differentiation n = 75
Not evaluable by at least 1 
criteria out of the 9 criteria of 
JRS 2000
*: Includes 1 patient with unknown place of onset
**: The number of cases with Pneumococcal pneumonia positivity syndrome by the antigen inspection were 221 examples in urine.
Fig. 2 – Initial diagnosis/differentiation of disease type.
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diagnosis was frequently used (in 39.8% of L. pneumophila
pneumonia cases and 59.8% of pneumococcal pneumonia
cases). Incorporating the results of rapid diagnosis into the
differentiation of disease type at initial consultation is also
thought to be an issue for the future.
Examination of the status of antimicrobial agent use in
initial treatment revealed low use of recommended antimi-
crobial agents, which only accounted for approximately one-
third of cases. Moreover, the efficacy of recommended
antimicrobial agents was similar to that of non-recom-
mended antimicrobial agents.
Antimicrobial agent selection for empiric treatment accord-
ing to JRS 2005 depends on the results of disease type
differentiation at initial consultation and place of treatment,
but not on severity. The efficacy of recommended antimicro-
bial agents in inpatients was 91.8% (112/122 patients) in mild
cases, 78.9% (161/204 patients) in moderate cases, and 78.7%
(59/75 patients) in severe and very severe cases. This suggests
that further investigation, including consideration of severity,
will be necessary in the future for the selection of anti-
microbial agents for empiric treatment.5. Conclusions
JRS 2005 is advantageous in terms of reducing the number of
items used in disease type differentiation while providing
approximately the same level of accuracy. The efficacy of
recommended antimicrobial agents used for the initial
treatment was significantly higher than that of inappropriate
antimicrobial agents used in outpatients, and the efficacy of
recommended antimicrobial agents was not lower than that
of excessive dosage in both inpatients and outpatients. This is
thought to demonstrate that the recommended antimicrobial
agents are appropriate.Conflict of interest
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Outpatients n = 30 Outpatients n = 282 Outpatients n = 139 Outpatientz n = 89 Outpatients n = 0
Inpatients n = 96 Inpatients n = 626 Inpatients n = 172 Inpatients n = 430 Inpatients n = 10
Suspected atypical pneumonia n = 131
Not atypical and not bacterial pneumonia n = 289
Not atypical pneumonia n = 235
Not bacterial pneumonia n = 253
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n = 451
Causative organism unknown or 
missing bacteriological testing* n = 1346
Mild
n = 857
Moderate
n = 808*
n = 894
Very severe
n = 46
InpatientsOutpatients Inpatients
Severe
 n = 164
Known causative organism
Outpatients
Bacterial pneumonia other than 
pneumococcal pneumonia **  n = 198
Pneumococcal pneumonia**
n = 321
n = 89 n = 440
Atypical pneumonia
n = 126
L. pneumophila pneumonia
n = 10n = 519
Bacterial pneumonia**Unknown causative 
organism, n = 908
Not tested*
n = 312
*: Includes 1 patient with unknown place of onset
**: Includes 45 patients with mixed infection (27 patients with pneumococcal pneumonia and 18 patients with bacterial pneumonia other than pneumococcal)
Fig. 3 – Summary of suspected and determined causative organisms.
Table 3 – Specificity and sensitivity of differentiation of atypical pneumonia using JRS 2005 and 2000.
Mycoplasma pneumoniae
pneumonia
Chlamydia pneumoniae
pneumonia
Atypical pneumonia
JRS 2005 (6 criteria)
Sensitivity (%) 80.4 30.0 71.0
(n/n) (164/204) (30/100) (174/245)
Specificity (%) 74.5 62.3 74.4
(n/n) (580/779) (550/883) (549/738)
JRS 2005 (5 criteria)
Sensitivity (%) 86.8 43.0 79.2
(n/n) (177/204) (43/100) (194/245)
Specificity (%) 63.4 52.5 63.7
(n/n) (494/779) (464/883) (470/738)
JRS 2000 (9 criteria)
Sensitivity (%) 69.6 19.0 59.2
(n/n) (142/204) (19/100) (145/245)
Specificity (%) 84.1 72.0 83.6
(n/n) (655/779) (636/883) (617/738)
The example of 2 or more of theMycoplasma pneumoniae and Chlamydia pneumoniae infectious diseases calculated sensitivity and the peculiarity
degree by the repetition count.
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Table 4 – Use and efficacy of treatment with antimicrobial agents recommended and non-recommended by JRS 2005 (6
criteria).
Initial diagnosis/differentiation Antimicrobial agent
Total no.
of patients
Efficacy of treatment w
2 test
n (%)a NEb P value
Total
Total Recommended 641 531 87.0 31
0.932
Non-recommended 1144 949 86.9 52
Outpatients Recommended 223 199 95.2 14
0.079
Non-recommended 282 244 91.0 14
Inpatients Recommended 418 332 82.8 17
0.208
Non-recommended 862 705 85.6 38
Suspected atypical pneumonia
Total Recommended 228 201 92.6 11
0.735
Non-recommended 334 292 91.8 16
Outpatients Recommended 150 134 95.7 10
0.451
Non-recommended 150 134 93.7 7
Inpatients Recommended 78 67 87.0 1
0.439
Non-recommended 184 158 90.3 9
Suspected bacterial pneumonia
Total Recommended 410 327 83.8 20
0.641
Non-recommended 803 652 84.9 35
Outpatients Recommended 73 65 94.2 4
0.164
Non-recommended 132 110 88.0 7
Inpatients Recommended 337 262 81.6 16
0.293
Non-recommended 671 542 84.3 28
Legionella pneumophila pneumonia
Total Recommended 3 3 100 0
1c
Non-recommended 7 5 83.3 1
Outpatients Recommended 0 0 – 0
–
Non-recommended 0 0 – 0
Inpatients Recommended 3 3 100 0
1c
Non-recommended 7 5 83.3 1
a Number of patients for whom the agent was effective/total number of patients evaluable for efficacy.
b NE ¼ not evaluable; the number of patients who were not evaluable for efficacy.
c Fisher’s exact test.
Table 5 – Efficacy of non-recommended antimicrobial agents (JRS 2005, 6 criteria) according to reason for use.
Classification
Efficacy rate (%) (n/n)
Excessive Inadequate Inappropriate Unknown Total Recommended
Outpatients 93.5 (215/230) 80.0 (8/10) 75.0n (21/28)  (0/0) 91.0 (244/268) 95.2 (199/209)
Inpatients 86.8 (236/272) 84.4 (384/455) 86.7 (78/90) 100 (7/7) 85.6 (705/824) 82.8 (332/401)
Total 89.8 (451/502) 84.3 (392/465) 83.9 (99/118) 100 (7/7) 86.9 (949/1092) 87.0 (531/610)
n Po0.05 (Fisher’s exact test).
R E S P I R ATO RY I N V E S T I G AT I O N 50 ( 2012 ) 23 –32 31from Astellas Pharma Inc., Daiichi Sankyo Co., Ltd.; chairs
endowed departments from KYORIN Pharmaceutical Co., Ltd.,
Shionogi & Co., Ltd., Daiichi Sankyo Co., Ltd., Taisho
Pharmaceutical Co., Ltd., Dainippon Sumitomo Pharma Co.,
Ltd., Taiho Pharmaceutical Co., Ltd., Toyama Chemical Co.,
Ltd., Meiji Seika Pharma Co., Ltd.
Shigeru Kohno received lecture fees from Taisho Toyama
Pharmaceutical Co., Ltd., Pfizer Japan Inc., Astellas Pharma
Inc., Daiichi Sankyo Co., Ltd., Shionogi & Co., Ltd., Dainippon
Sumitomo Pharma Co., Ltd., MSD K.K., GlaxoSmithKline K.K.;
received manuscript fees from Taisho Toyama Pharmaceu-
tical Co., Ltd., Pfizer Japan Inc., Astellas Pharma Inc., DaiichiSankyo Co., Ltd., Shionogi & Co., Ltd., Dainippon Sumitomo
Pharma Co., Ltd., MSD K.K., GlaxoSmithKline K.K.; received
researching founding from KYORIN Pharmaceutical Co., Ltd.,
Pfizer Japan Inc., Meiji Seika Kaisha, Ltd.; received Subsidies
or Donations from MSD K.K., Shionogi & Co., Ltd., Meiji Seika
Kaisha, Ltd., Daiichi Sankyo Co., Ltd., Astellas Pharma Inc.,
Dainippon Sumitomo Pharma Co., Ltd., Takeda Pharmaceu-
tical Company Limited, Ono Pharmaceutical Co., Ltd., Chugai
Pharmaceutical Co., Ltd., Pfizer Japan Inc.
Yoshihito Niki received lecture fees from Daiichi Sankyo Co.,
Ltd., Astellas Pharma Inc., Pfizer Japan Inc., Bayer Yakuhin, Ltd.,
Taisho Toyama Pharmaceutical Co., Ltd., Convex Inc., GlaxoS-
R E S P I R ATO RY I N V E S T I G AT I O N 50 ( 2012 ) 23 –3232mithKline K.K., Kyowa Kikaku Ltd., Dainippon Sumitomo
Pharma Co., Ltd., Shionogi & Co., Ltd.; received manuscript fees
from Taiko Pharmaceutical Co., Ltd., Nankodo Co., Ltd.; received
Subsidies or Donations from Dainippon Sumitomo Pharma Co.,
Ltd.; chairs endowed departments from Toyama Chemical Co.,
Ltd., Taiho Pharmaceutical Co., Ltd., KYORIN Pharmaceutical
Co., Ltd., Shionogi & Co., Ltd., Astellas Pharma Inc., Taisho
Pharmaceutical Co., Ltd., Kaken Pharmaceutical Co., Ltd.,
Janssen Pharmaceutical K.K., Meiji Seika Kaisha, Ltd.
Hajime Goto, Toshiharu Matsushima, Shosaku Abe, Nobuyuki
Aoki, Kaoru Shimokata, Keiichi Mikasa, they have no potential
conflict of interest.
Acknowledgments
We wish to express our deep appreciation to Taisho Toyama
Pharmaceutical Co., Ltd., Taisho Pharmaceutical Co., Ltd.,
and Toyama Chemical Co., Ltd. for their cooperation in this study.R E F E R E N C E S
[1] Community-acquired Pneumonia Medical Care Guideline—
Drafting Committee of the Japanese Respiratory Society.
Guidelines on Respiratory Infections—Basic Concepts in the
Medical Care of Community-acquired Pneumonia in Adults.
Tokyo: Japanese Respiratory Society; 2000 (in Japanese).
[2] Committee for the Japanese Respiratory Society Guidelines for
the Management of Respiratory Infections. Guidelines for the
management of community acquired pneumonia in adults
(revised edition). Respirology 2006;11:S79–133.
[3] The Committee for the Respiratory System, Japan Society of
Chemotherapy. Clinical evaluation methods for new antimi-
crobial agents to treat respiratory infections. Jpn J Chemother
1997;45:762–78 (in Japanese).
[4] Watanabe A, Matsushima T, Kohno S, et al. Results of survey
of adult community-acquired pneumonia utilizing flow chart
of diagnostic guideline for management of respiratory infec-
tions. J Jpn Respir Soc 2003;41:781–96 (in Japanese).
